RALEIGH, N.C. and HOUSTON, July 14, 2011 (GLOBE NEWSWIRE) -- InoLife Technologies, Inc. (OTCBB:INOL), a service based healthcare products development, integration and marketing company, announced today its acquisition of all of the outstanding shares of common stock of Stemtide, Inc., (“STEMTIDE”). The principal asset of STEMTIDE is the perpetual fully paid and non-exclusive manufacturing and marketing rights to the STEMTIDE Age-Reversing Products, throughout the United States, whose products are licensed from an affiliate of the principal shareholders of InoLife. Consideration for the acquisition was 50 million shares of INOL stock and residual payments of 10% of the gross profits derived from the sale of the Age-Reversing Products.
